申请人:Pfizer Inc.
公开号:US03944524A1
公开(公告)日:1976-03-16
A series of novel 1-piperidinesulfonylurea compounds derived from a nitrogen-containing monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxynicotinic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endomethyl)-3-4-[2-(2-methoxynicotinamido )ethyl]-1-piperidinesulfonyl}urea is a most preferred embodiment.
一系列新型1-哌啶磺酰脲类化合物由含氮单羧酸与适当的磺酰胺与有机异氰酸酯或三取代脲等反应制备而成。所得的磺酰脲类可用于治疗口服降血糖药物。典型成员包括从2-甲氧基烟酸酸衍生的化合物,其中1-(双环[2.2.1]庚-5-烯-2-基-内甲基)-3-4-[2-(2-甲氧基烟酰胺)乙基]-1-哌啶磺酰}脲是最优选的实施形式。